Background: Cervical adenocarcinomas are a heterogeneous group of tumors, accounting for approximately 20% of all cervical cancers. Many clinical data suggest that the activity of PARPi inhibitors may not be limited to BRCA mutated tumours and may involve the homologous recombination pathway. At present, there are few data available on the activity of PARPi in endometrial and cervical cancers. And poly-(ADP)-ribose polymerase inhibitors (PARPi) are changing clinical practice in the BRCA mutant patients with cervical cancer. Case Description: Here, we report the case of a 66-year-old female patient admitted to the hospital due to abnormal vaginal bleeding. She was diagnosed with advanced cervical adenocarcinomas, and received chemotherapy followed by Paclitaxe and Cisplatin in the first-line. However, after one cycle of treatment, the patient's disease progressed. To identify more opportunities for treatment, the biopsy tissue was genetic tested and found BRCA1 exon 23 mutation and PD-L1 positive score, which motivated chemotherapy combined with immune checkpoint inhibitors, and the tumor size decreased. However, because of the side effects of from long-term chemotherapy, the patient chosen Olaparib treatment in the later stage. The patient benefited long-term disease control for about 24 months. Conclusions: This case might support the strategy that PARPi could be an alternative treatment for cervical adenocarcinoma patients with BRCA1 mutation in the future.